{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T09:45:10Z","timestamp":1782726310187,"version":"3.54.5"},"reference-count":22,"publisher":"PAGEPress Publications","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Reports"],"abstract":"<jats:p>Obesity impacts both the clinical management and therapeutic strategies for psoriasis. This study aims to describe the use of biological medicines in treating obese patients with moderate-to-severe psoriasis. We conducted a retrospective cohort study (2007-2022) of obese patients who initiated biological treatments for moderate-severe psoriasis. The primary outcome was the number of biological treatment lines required to achieve an optimal or adequate Psoriasis Area and Severity Index (PASI) score reduction. Secondary outcomes included the duration of biological use and reasons for discontinuation. We included 58 patients (mean age 50 years, body mass index [BMI] 35.9 kg\/m2, psoriasis duration 16.5 years). Biological treatments enabled 77.6% (45) of patients to achieve an optimal response, and 87.9% (51) achieved an adequate response. The median time-to-response was 2-7 months, with the greatest improvements seen with adalimumab, etanercept, and ustekinumab. The primary reason for discontinuation was lack of effectiveness (50% of first-line treatments). This study suggests that systemic biologics are effective for obese psoriasis patients and emphasizes the need for close monitoring of reasons that lead to discontinuation. As biologics evolve, refining guidelines will be essential for optimizing psoriasis management in obese patients.<\/jats:p>","DOI":"10.4081\/dr.2026.10247","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T14:42:10Z","timestamp":1782225730000},"source":"Crossref","is-referenced-by-count":0,"title":["A cohort study of obese patients with moderate-to-severe psoriasis using biological medicines in Catalonia, Spain"],"prefix":"10.4081","author":[{"given":"Judit","family":"Riera-Arnau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Mollet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Bellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Boy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Gonz\u00e1lez-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f2nica","family":"Sabat\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ballar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicen\u00e7","family":"Garc\u00eda-Patos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gl\u00f2ria","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2549","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"41078","doi-asserted-by":"crossref","unstructured":"1. Chiricozzi A, Gisondi P, Girolomoni G. The pharmacological management of patients with comorbid psoriasis and obesity. Expert Opin Pharmacother 2019;20:863-72.","DOI":"10.1080\/14656566.2019.1583207"},{"key":"41079","unstructured":"2. Programa d'Harmonitzaci\u00f3 Farmacoterap\u00e8utica. [Plaque psoriasis treatment: outcomes assessment report]. Servei Catal\u00e0 de la Salut; 2022. [accessed October 17, 2024] Available from: https:\/\/scientiasalut.gencat.cat\/handle\/11351\/7116."},{"key":"41080","doi-asserted-by":"crossref","unstructured":"3. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: A review. JAMA 2020;323:1945-60.","DOI":"10.1001\/jama.2020.4006"},{"key":"41081","unstructured":"4. Programa d\u2019Harmonitzaci\u00f3 Farmacoterap\u00e8utica. [Clinical criteria for the use of adalimumab, bimekizumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab, ustekinumab, and deucravacitinib in the treatment of moderate-to-severe plaque psoriasis in adult patients]. [accessed October 17, 2024] Available from: https:\/\/catsalut.gencat.cat\/web\/.content\/minisite\/catsalut\/proveidors_professionals\/medicaments_farmacia\/harmonitzacio\/informes\/_compartits\/Psoriasi\/criteris-clinics-tractaments-dirigits-psoriasi-v2.pdf"},{"key":"41082","doi-asserted-by":"crossref","unstructured":"5. Paroutoglou K, Papadavid E, Christodoulatos GS, Dalamaga M. Deciphering the association between psoriasis and obesity: current evidence and treatment considerations. Curr Obes Rep 2020;9:165-78.","DOI":"10.1007\/s13679-020-00380-3"},{"key":"41083","doi-asserted-by":"crossref","unstructured":"6. Carrascosa JM, Rocamora V, Fernandez-Torres RM, et al. Obesidad y psoriasis: naturaleza inflamatoria de la obesidad, relaci\u00f3n entre psoriasis y obesidad e implicaciones terap\u00e9uticas. Actas Dermosifiliogr 2014;105:31-44.","DOI":"10.1016\/j.ad.2012.08.003"},{"key":"41084","doi-asserted-by":"crossref","unstructured":"7. Aranceta-Bartrina J, P\u00e9rez-Rodrigo C, Alberdi-Aresti G, et al. Prevalencia de obesidad general y obesidad abdominal en la poblaci\u00f3n adulta espa\u00f1ola (25-64 a\u00f1os) 2014-2015: Estudio ENPE. Rev Esp Cardiol 2016;69:579-87.","DOI":"10.1016\/j.recesp.2016.02.010"},{"key":"41085","doi-asserted-by":"crossref","unstructured":"8. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet 2021;397:1301-15.","DOI":"10.1016\/S0140-6736(20)32549-6"},{"key":"41086","doi-asserted-by":"crossref","unstructured":"9. Scala E, Megna M, Amerio P, et al. Patients\u2019 demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis. PLoS One 2020;15.","DOI":"10.1371\/journal.pone.0237267"},{"key":"41087","doi-asserted-by":"crossref","unstructured":"10. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-84.","DOI":"10.1016\/S0140-6736(08)60726-6"},{"key":"41088","doi-asserted-by":"crossref","unstructured":"11. Almenara-Blasco M, Gracia-Caza\u00f1a T, Poblador-Plou B, et al. Multimorbidity of psoriasis: a large-scale population study of its associated comorbidities. J Clin Med 2024;13:492.","DOI":"10.3390\/jcm13020492"},{"key":"41089","doi-asserted-by":"crossref","unstructured":"12. Caiazzo G, Fabbrocini G, Di Caprio R, et al. Psoriasis, cardiovascular events, and biologics: lights and shadows. Front Immunol 2018;9:1668.","DOI":"10.3389\/fimmu.2018.01668"},{"key":"41090","doi-asserted-by":"crossref","unstructured":"13. Pe\u00f1a C. [Latent tuberculosis: current diagnosis and treatment]. Rev Chil Enferm Respir 2022;38:123-30.","DOI":"10.4067\/s0717-73482022000300123"},{"key":"41091","doi-asserted-by":"crossref","unstructured":"14. Krantz \u00c5, Carrero JJ, Yang Y, et al. Psoriasis\/psoriatic arthritis patients' long-term treatment patterns and adherence to systemic treatments monitoring recommendations. Acta Derm Venereol 2023;103.","DOI":"10.2340\/actadv.v103.6505"},{"key":"41092","doi-asserted-by":"crossref","unstructured":"15. Menter A, Gordon KB, Leonardi CL, et al. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol 2010;63:448-56.","DOI":"10.1016\/j.jaad.2009.09.040"},{"key":"41093","doi-asserted-by":"crossref","unstructured":"16. Chiricozzi A, Burlando M, Caldarola G, et al. Ixekizumab effectiveness and safety in the treatment of moderate-to-severe plaque psoriasis: a multicenter, retrospective observational study. Am J Clin Dermatol 2020;21:441-7.","DOI":"10.1007\/s40257-019-00490-2"},{"key":"41094","doi-asserted-by":"crossref","unstructured":"17. Gisondi P, Conti A, Galdo G, et al. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br J Dermatol 2013;168:1124-7.","DOI":"10.1111\/bjd.12235"},{"key":"41095","doi-asserted-by":"crossref","unstructured":"18. Pinter A, Schwarz P, Gerdes S, et al. Biologic treatment in combination with lifestyle intervention in moderate to severe plaque psoriasis and concomitant metabolic syndrome: rationale and methodology of the METABOLyx randomized controlled clinical trial. Nutrients 2021;13:3015.","DOI":"10.3390\/nu13093015"},{"key":"41096","doi-asserted-by":"crossref","unstructured":"19. Trevisan G, Germi L, Naldi L. Erythrodermic psoriasis improved by Tildrakizumab. Dermatol Reports 2022;14:9448.","DOI":"10.4081\/dr.2022.9448"},{"key":"41097","unstructured":"20. Bravo EA, Bar N, Paucar S, et al. Reducci\u00f3n del PASI en pacientes con psoriasis moderada-severa tratados con terapia biol\u00f3gica. Experiencia en hospital de tercer nivel peruano. Med Cutan Iber Lat Am 2016;44:41-4."},{"key":"41098","doi-asserted-by":"crossref","unstructured":"21. Puig L, Bordas X, Carrascosa JM, et al. Documento de consenso sobre la evaluaci\u00f3n y el tratamiento de la psoriasis moderada\/grave del Grupo Espa\u00f1ol de Psoriasis de la Academia Espa\u00f1ola de Dermatolog\u00eda y Venereolog\u00eda. Actas Dermosifiliogr 2009;100:277-86.","DOI":"10.1016\/S0001-7310(09)70821-X"},{"key":"41099","doi-asserted-by":"crossref","unstructured":"22. Renzo LD, Saraceno R, Schipani C, et al. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-\u03b1 treatment. Dermatol Ther 2011;24:446-51.","DOI":"10.1111\/j.1529-8019.2011.01439.x"}],"container-title":["Dermatology Reports"],"original-title":[],"link":[{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10247\/9955","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10247\/9954","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T09:01:17Z","timestamp":1782723677000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/view\/10247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":22,"URL":"https:\/\/doi.org\/10.4081\/dr.2026.10247","relation":{},"ISSN":["2036-7406","2036-7392"],"issn-type":[{"value":"2036-7406","type":"electronic"},{"value":"2036-7392","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,23]]}}}